Wanbury Limited
NSE: WANBURY · Pharmaceuticals · sector
₹166.42NSE close 2026-10-26
Key numbers
Market cap₹581 cr
Price₹166.42
52w high / low₹359 / ₹162
P/E9.6xSector median 27.9x
P/B4.0xSector median 2.9x
Book value₹41.3
Dividend yield–Sector median 0.48%
ROE54.9%Sector median 11.7%
ROCE22.6%Sector median 12.3%
OPM14.6%Sector median 14.0%
Debt / equity1.49xSector median 0.16x
EV/EBITDA8.3xSector median 18.6x
Interest cover2.7x
Current ratio1.19x
Sales growth 3y+9.2%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.32x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹8 cr vs borrowings ₹215 cr (FY26): borrowings are higher by ₹208 cr.
- Borrowings rose in each of the last 3 years (₹64 cr → ₹215 cr).
- Operating profit covered interest 2.7x in the last 12 months.
- 5.49% of the promoters' shares are pledged (2.4% of all shares).
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY25, FY24, FY22).
- Revenue was higher than a year earlier in 2 of the last 4 quarters.
- Other income was 2% of net profit in the last 12 months.
- Debtor days went from 57 (FY24) to 80 (FY26).
- No dividend in the last 5 financial years.
- Price ₹166.42 on 2026-10-26: -53.6% from the 52-week high, +3.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹344.75 · low ₹160.29
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 161 | 133 | 172 | 163 | 160 | 162 | 165 | 166 |
| EBITDA | 20 | 14 | 30 | 24 | 26 | 27 | 26 | 16 |
| OPM % | 12.4% | 10.5% | 17.2% | 15.0% | 16.1% | 16.4% | 15.9% | 9.8% |
| Other income | 2 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 8 | 1 | 20 | 13 | 15 | 16 | 22 | 3 |
| EPS (₹) | 2.44 | 0.76 | 6.18 | 4.12 | 4.58 | 4.52 | 7.33 | 0.93 |
| Revenue YoY | -0.7% | +21.7% | -4.3% | +1.5% | ||||
| Profit YoY | +89.3% | +1,191.8% | +7.1% | -76.0% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 511 | 500 | 576 | 600 | 650 | 653 |
| EBITDA | 112 | 23 | 70 | 76 | 103 | 95 |
| Net profit | 81 | -10 | 30 | 31 | 66 | 56 |
| EPS (₹) | 26.88 | -6.18 | 9.29 | 9.32 | 20.55 | 17.36 |
| Revenue growth | -2.3% | +15.2% | +4.1% | +8.5% | +3.6% | |
| Profit growth | -112.8% | – | +0.4% | +116.6% | +30.0% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +9.2% | +10.6% | +3.6% |
| Net profit | – | – | +30.0% |
| EPS | – | – | – |
| Share price | – | -12.2% (2y) | -20.2% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | -7 | 28 | 59 | 144 |
| Borrowings | – | 64 | 110 | 173 | 215 |
| Cash & equivalents | – | 4 | 6 | 13 | 8 |
| Total assets | – | 302 | 343 | 414 | 518 |
| Fixed assets | – | 152 | 149 | 190 | 227 |
| Capital work in progress | – | 2 | 3 | 5 | 25 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 68 | 89 | 114 | 143 |
| Inventory | – | 22 | 36 | 38 | 51 |
| Payables | – | 148 | 0 | 138 | 107 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 38 | 20 | 4 | 26 | 32 |
| Cash from investing | 1 | -9 | -17 | -51 | -56 |
| Cash from financing | -26 | -32 | 15 | 26 | 22 |
| Capex | 0 | 0 | 0 | 49 | 59 |
| Free cash flow | 38 | 20 | 4 | -23 | -28 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 143.2% | 108.8% | 51.5% | 45.8% |
| ROCE % | – | 19.5% | 43.5% | 28.6% | 24.9% |
| Debtor days | – | 50 | 57 | 70 | 80 |
| Inventory days | – | 27 | 43 | 47 | 67 |
| Payable days | – | 178 | 0 | 172 | 142 |
| Cash conversion cycle (days) | – | -101 | 100 | -55 | 5 |
| Working capital days | – | -126 | -35 | 11 | 21 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 42.98% |
| FIIs | 0.71% |
| DIIs | 0.02% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 56.28% |
| Quarter | Mar 2025 | Jun 2025 | Sep 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 39.76% | 39.63% | 43.09% | 43.09% | 43.07% | 43.02% | 43.02% | 42.98% |
| Promoter group | % |
|---|---|
| Expert Chemicals (India) PVT Ltd | 34.33% |
| Kingsbury Investments INC | 8.65% |
| Public holders above 1% | % |
|---|---|
| Suresh Bhatia | 3.11% |
| Authum Investment and Infrastructure Limited | 2.08% |
| Sharmin Nasser | 1.24% |
| Basava Sankararao Kolli | 1.16% |
20,432 shareholders. Pledged: 5.49% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| WANBURY | ₹581 cr | 9.6x | 4.0x | 54.9% | 22.6% | 14.6% | +9.2% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-09-20 | Other | Annual General Meeting |
| 2023-11-10 | Other | Extra Ordinary General Meeting |
| 2023-09-20 | Other | Annual General Meeting |
| 2023-08-14 | Other | Extra-Ordinary General Meeting |
| 2022-09-20 | Other | Annual General Meeting |
| 2021-09-17 | Other | Annual General Meeting |
| 2021-03-10 | Other | Extra Ordinary General Meeting |
| 2020-09-18 | Other | Annual General Meeting |
| 2019-09-20 | Other | Annual General Meeting |
| 2018-09-18 | Other | Annual General Meeting |
| 2017-09-21 | Other | Annual General Meeting |
| 2016-09-21 | Other | Annual General Meeting |
| 2015-09-18 | Other | Annual General Meeting |
| 2015-03-12 | Other | Annual General Meeting |
| 2013-09-26 | Other | Annual Book Closure |
| 2012-09-13 | Other | Annual General Meeting |
| 2011-09-19 | Other | Annual General Meeting |
| 2010-07-29 | Dividend | Dividend-Rs.1/- Per Share |
| 2009-09-17 | Other | Annual General Meeting |
| 2009-03-12 | Dividend | Agm/Dividend - 5% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | WANBURY |
| BSE code | 524212 |
| ISIN | INE107F01022 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.